Moleculin Biotech Inc (MBRX)
4.77
+0.13
(+2.80%)
USD |
NASDAQ |
May 31, 16:00
4.78
+0.01
(+0.21%)
After-Hours: 20:00
Moleculin Biotech Research and Development Expense (Annual): 19.49M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 19.49M |
| December 31, 2022 | 18.97M |
| December 31, 2021 | 14.42M |
| December 31, 2020 | 12.76M |
| Date | Value |
|---|---|
| December 31, 2019 | 11.01M |
| December 31, 2018 | 9.728M |
| December 31, 2017 | 4.545M |
| December 31, 2016 | 1.496M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
11.01M
Minimum
2019
19.49M
Maximum
2023
15.33M
Average
14.42M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Merck & Co Inc | 30.53B |
| Lixte Biotechnology Holdings Inc | 0.8981M |
| Moderna Inc | 4.845B |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |